Armata Pharmaceuticals (ARMP) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Protara Therapeutics (TARA) over the past year, gaining 13.1% versus a loss of 50.9%. Over five years, ARMP leads with a +5.2% price change compared with -59.7% for TARA. Protara Therapeutics is the larger company by market cap ($162.8 million vs $135.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | TARA |
|---|---|---|
| Share price | $3.63 | $2.76 |
| Market cap | $134.97M | $162.81M |
| 1-day change | -5.96% | +3.96% |
| YTD return | -42.20% | -48.31% |
| 1-year return | +13.08% | -50.89% |
| 5-year return | +5.22% | -59.72% |
| EPS (TTM) | $-4.97 | $-1.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $7.82 |
| 52-week low | $3.14 | $2.51 |
| Distance from 52-week high | -77.78% | -64.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +382.09% | +833.21% |
| Average volume | 208.13K | 814.80K |
| Shares outstanding | 37.18M | 59.10M |
| Employees | 61 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed TARA by 64.0 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
ARMP vs TARA FAQ
Which is bigger, Armata Pharmaceuticals or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $162.81M compared with $134.97M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or TARA?
ARMP returned +13.08% over the past 12 months, compared with -50.89% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.